Choose Language
Select a language for news translation.
Written by Prosper Junior Bakiny for The Motley Fool -> Vertex Pharmaceuticals and Eli Lilly are both going after the non-opioid pain management market. Vert…
Eli Lilly and Company (NYSE: LLY ) is one of the best growth stocks to buy, according to billionaire Ray Dalio's Bridgewater Associates . On June 10, the US Fo…
Eli Lilly (Symbol: LLY) options are showing a volume of 20,775 contracts thus far today. That number of contracts represents approximately 2.1 million underlyi…
Eli Lilly and Company (NYSE: LLY ) is among the stocks with the best earnings growth for the next 3 years . On June 15, Eli Lilly and Company (NYSE:LLY) shared…
Written by Prosper Junior Bakiny for The Motley Fool -> Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent …
With a profit margin of 34.99% and net income of $20.64 billion (FY25), Eli Lilly and Company (NYSE: LLY ) ranks among the most profitable blue chip stocks to …
Jordi Visser argues Eli Lilly's AI infrastructure, proprietary metabolic data, and GLP-1 drugs could make it the world's largest company within 5 years. Lilly…
Written by Joe Tenebruso for The Motley Fool -> Investors are excited about retatrutide's potential. Rival drugmakers are finding it difficult to keep pace w…
At the Tribeca Festival, the director reunited with the cast of her film 30 years on and got candid about what the sapphic neo-noir meant to her then and now.
Two drugs make up nearly two-thirds of Eli Lilly 's (NYSE: LLY) top line, generating around $12.8 billion in revenues in the first quarter of 2026. The two dru…
Written by Reuben Gregg Brewer for The Motley Fool -> Eli Lilly is probably best known for its dominant GLP-1 drugs right now. The company's recent $3.8 bill…
